» Articles » PMID: 28371208

Changing Epidemiology of Elderly Small Cell Lung Cancer Patients over the Last 40 Years; a SEER Database Analysis

Overview
Journal Clin Respir J
Specialty Pulmonary Medicine
Date 2017 Apr 4
PMID 28371208
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Small cell lung cancer (SCLC) is a distinct clinical and pathological entity within the spectrum of lung cancer. It was observed that the relative age distribution of the disease changed over years.

Methods: Surveillance, epidemiology, and end results (SEER) database (1973-2013) was utilized to determine the incidence, presentation and treatment outcomes of elderly patients (>70 years) with SCLC. Join point regression analysis was then conducted to analyze age-adjusted trends in incidence for the elderly as well as the whole SCLC population. Survival analysis was conducted through Kaplan-Meier analysis. Clinicopathological characteristics and survival outcomes were compared between patients diagnosed at 70-79 years old and those older than 80 years old (octogenarian group).

Results: The proportion of elderly patients among all cases of SCLC increased from 23% in 1975 to 44% in 2010. Moreover, the proportion of elderly female patients among all cases of elderly SCLC increased from 25% in 1975 to 49% in 2010. When categorizing patients into four subgroups "70-74," "75-79," "80-84," and "85+", there was a trend toward a lower cancer-specific survival with increasing age (P < .0001). A limited improvement in 5 year survival was observed during the study period and it is less apparent as the age increases.

Conclusion: The proportion of elderly patients among all cases of SCLC has increased over the past 40 years. Further studies are needed to better select appropriate treatments for this subset of patients.

Citing Articles

Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.

Zhao K, Lu S, Niu J, Zhu H, Tian Y, Yu J BMC Cancer. 2025; 25(1):467.

PMID: 40087602 DOI: 10.1186/s12885-025-13880-z.


Acceptance of Illness and Health Behaviours of Patients with End-Stage Renal Disease Treated with Haemodialysis: A Single-Centre Study.

Hrenczuk M, Rudnicka W, Piatek T, Malkowski P Healthcare (Basel). 2025; 12(24.

PMID: 39765988 PMC: 11675093. DOI: 10.3390/healthcare12242562.


Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

Maheshwari S, Gentzler R J Thorac Dis. 2024; 16(9):6342-6346.

PMID: 39444913 PMC: 11494565. DOI: 10.21037/jtd-24-279.


Predictive model for totally implanted venous access ports‑related long‑term complications in patients with lung cancer.

Jia J, Fan X, Zhang W, Xu Z, Wu M, Zhan Y Oncol Lett. 2024; 28(1):326.

PMID: 38807672 PMC: 11130750. DOI: 10.3892/ol.2024.14459.


Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era.

Li H, Zhao Y, Ma T, Shao H, Wang T, Jin S Front Immunol. 2023; 14:1132482.

PMID: 37701437 PMC: 10493776. DOI: 10.3389/fimmu.2023.1132482.